Status:
COMPLETED
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally...
Eligibility Criteria
Inclusion
- Patients with schizophrenia treated with clozapine (200-900 mg/day), who gained at least 2.5 kg while on clozapine.
Exclusion
- Patients known to be allergic to aripiprazole
- Hospitalized patients
- Patients who have previously received study medication in an aripiprazole clinical study or who have participated in any clinical trial with an investigational agent within the past month.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00300846
Start Date
December 1 2005
End Date
July 1 2007
Last Update
November 8 2013
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Graz, Austria
2
Local Institution
Innsbruck, Austria
3
Local Institution
Vienna, Austria
4
Local Institution
Brno - Bohunice, Czechia